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Abstract
Objective—We previously reported association of co-occurrence of HLA-DRB1 shared epitope
(SE) and RANKL SNPs with younger age of RA onset in 182 rheumatoid factor positive (RF)
European American (EA) early RA patients. Here, we fine-mapped the 48 kb RANKL region in the
extended 210 EA RF-positive early RA cohort, sought replication of RA-associated SNPs in
additional 501 EA and 298 African-Americans (AA) RA cohorts, and explored functional
consequences of RA-associated SNPs.
Methods—SNP genotyping was conducted using pyrosequencing or TaqMan PCR assays.
Associations of rs7984870 with RANKL expression in plasma, PBMC and isolated T cells were
quantified using ELISA and RT-PCR. Site-directed mutagenesis of rs7984870 within the 2kb
RANKL promoter was performed to drive the luciferase reporter gene in osteoblast and stromal
cell lines. Interaction of DNA and protein was determined by electrophoretic mobility shift assay.
Results—A single promoter SNP rs7984870 was consistently significantly associated with
earlier age of RA onset in 3 independent seropositive (RF or anti-cyclic citrullinated peptide
antibody positive) RA cohorts but not in seronegative RA patients. The risk C allele of rs7984870
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conferred 2-fold higher plasma RANKL levels in RF-positive RA patients, significantly elevated
RANKL mRNA expression in activated normal T cells, and increased promoter activity after
stimulation in vitro via differential binding to transcription factor SOX5.
Conclusion—The RANKL promoter allele that increased transcriptional levels upon stimulation
might promote interaction between activated T cells and dendritic cells, predisposing to younger
RA onset in seropositive EA and/or AA individuals.
Rheumatoid arthritis (RA) is characterized by chronic inflammation and destruction of
cartilage and bone. The etiology of RA is not clearly defined, but it is presumed that
environmental factors trigger the disease in genetically predisposed individuals. The
strongest genetic contribution to RA susceptibility is the HLA - class II alleles that contain a
common amino acid motif called the “shared epitope” (SE), which is also a risk factor for
disease progression and development of extraarticular manifestations (1). In addition to the
SE alleles, multiple gene variants, including PTPN22, PADI4, FCRL3, CTLA4, STAT4,
TRAF1/C5, CD40, IL2RB, IL21, PRKCQ, KIF5A, AFF3, REL, TNFAIP3, CD28, PRDM1
and CD2/CD58 have been associated with susceptibility to RA; however, causal variants of
many of these loci remain elusive (2–5). Anti-cyclic citrullinated peptide antibody (ACPA)
is highly specific for RA and can be detected years before the first clinical manifestations as
a putative predictor for developing RA. ACPA production is associated with HLA-DRB1,
PTPN22, TRAF1/C5, CD40, FCGR3A, STAT4, REL and PADI4 alleles (6–11), as well as
with environmental factors, primarily smoking (12), suggesting different pathophysiologic
mechanisms underlying seropositive and seronegative RA.
Receptor activator of nuclear factor κB ligand (RANKL [OMIM 602642]), a type II
membrane protein of the tumor necrosis factor family (TNFSF11), is expressed on
osteoblasts, stromal cells, activated T cells, B cells (13) and megakaryocytes (14). The
RANKL, located on chromosome 13q14, encodes three isoforms: RANKL1 and RANKL2
are both transmembrane proteins with the latter lacking an intracellular domain; RANKL3 is
a soluble protein containing neither an intracellular nor a transmembrane domain (15). A
deficiency of RANKL, the key molecule mediating osteoclast development, activity, and
survival (16), leads to osteoporosis and severe skeletal abnormalities in the murine model
(17). Apart from its importance in osteoclastogenesis, RANKL participates in immune
regulation by mediating differentiation of T and B lymphocytes, prolonging survival of
mature dendritic cells (DCs), promoting activation of monocytes, and participating in the
development of lymph nodes and medullary thymic epithelial cells (18). In RA, local and
systemic increased RANKL levels are associated with bone resorption, suggesting a pivotal
role in mediating bone erosion (19). Importantly, co-localization of RANKL and RANK
expression at the site of DC and T cell interaction in rheumatoid synovia and lymph nodes
may represent a direct link between cell-mediated immunity and bone destruction in RA
(20).
We have previously observed the association of younger age of RA onset with the presence
of HLA-DRB1*04 and RANKL polymorphisms in 182 RF+ EA RA patients (21). An
interaction between SE and RANKL polymorphisms was associated with a mean 18 years
younger age at RA onset in this cohort. Here, we used the enlarged EA RF+ RA cohort as a
discovery panel to fine map RANKL variants predisposing to early RA onset, replicated in
independent EA and AA early RA cohorts and tested this genetic association in EA RF+
polyarticular juvenile idiopathic arthritis (JIA) patients. Finally, we characterized functional
properties of the identified and confirmed RA-associated SNP in three seropositive RA
cohorts.
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The present study included 4 independent cohorts (3 RA and 1 JIA) (Table 1). The three RA
cohorts were early RA long-term observational studies including 1) Discovery panel, 210
EA RF+ early RA patients were from the Western Consortium of Practicing
Rheumatologists (WCPR cohort) (22), which had been enlarged from the 182 EA patients
reported (21); 2) Replication panel 1, 501 independent EA early RA patients were from the
Brigham Rheumatoid Arthritis Sequential Study registry (BRASS cohort); 3) Replication
panel 2, 298 patients who were participating in the Consortium for the Evaluation of AAs
with Early Rheumatoid Arthritis Registry (CLEAR cohort) (23). We also tested the genetic
association in 80 EA RF+ polyarticular JIA patients recruited from Cincinnati's Children
Hospital Medical Center, OH. All RA patients fulfilled the American College of
Rheumatology 1987 revised classification criteria for RA (24). Early RA was defined as
those patients who enrolled within 24 months after symptom onset and before disease-
modifying antirheumatic drugs (DMARDs) therapy. This study was approved by appropriate
institutional review boards.
Genotyping methods
SNPs spanning a 48 kb region from 7.3 kb upstream to 6.7 kb downstream of RANKL
transcribed sequence were surveyed in the NCBI-dbSNP build 36 database. A total of 16
SNPs were genotyped in this study, including 5 promoter, 7 intronic, one 3' untranslated
region (UTR), and three 3'downstream RANKL polymorphisms (Figure 1B). Among these
16 SNPs, 9 tag EA haplotypes throughout dbSNP database 124, 125 and 126, 1 promoter
and 3 intronic SNPs create putative transcription factor binding sites, 1 SNP has been
associated with low bone mineral density in men (25) and 2 SNPs were tested in our
previous study (21). Genomic DNA was isolated from blood mononuclear cells by the
standard protocol. Genotyping of RANKL SNPs was determined using PCR pyrosequencing
as described (20), except rs5803141, which was genotyped using fluorescence-based PCR.
In the BRASS cohort, SNPs rs7984870, rs9525641 and rs1054016 were genotyped by
TaqMan real-time PCR assays (Applied Biosystems). HLA–DRB1 genotyping were
determined by DNA-based sequence-specific oligonucleotide probe assay, AlleleSEQR
HLA–DRB1 reagent kit or allele-specific polymerase chain reaction as described elsewhere
(26–28).
ELISA
Concentrations of soluble RANKL levels in plasma of 23 RA patients at baseline and 24
normal controls were quantified using a commercial ELISA kit from ALPCO Diagnostics
(Salem, NH).
Real-Time PCR
Two isoforms in RANKL transcript levels (isoform1: NM003701.2 and total RANKL
transcript: NM033012.2) in PBMC from 38 EA normal controls were measured using ABI
TaqMan assay. Relative RANKL expression in PBMCs and T cells was normalized using the
expression level of CD4 and ribosomal protein (RPLPO), respectively and calculated by the
2−Δ Δ Ct method.
Cells cultures
Primary T cells were purified from peripheral blood of 8 healthy volunteers (4 CC and 4 GG
genotype for rs7984870) using a T-rosette purification kit (StemCell Technologies), which
were 93% CD3+ by flow cytometry. 4 × 105 T cells were plated onto 12 well plates in the
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presence or absence of 20ng/ml IL-2 (R&D Systems) for 24h or 48h, and then harvested to
perform Real-time PCR assays.
Site-directed mutagenesis
The RANKL promoter region (−1 bp to −2 kb relative to the transcription start site) was
previously cloned into the luciferase reporter pGL2 Basic vector (a kind gift from Dr.
Sakamuri V. Reddy) (29). The plasmids for −1816 G/G in the RANKL promoter region were
mutated into −1816 C/C using the QuikChange Lightning Site-Directed Mutagenesis kit
(Stratagene). Accuracy of mutagenesis was confirmed by sequence analysis.
Cell transfection
Five microgrammes of RANKL promoter/luciferase fusion plasmid DNA or empty vector
(pGL4) were transfected into human stromal cells SAKA-T and osteoblast cells hFOB 1.19
using Lipofect-AMINE kit (Invitrogen) and 100ng of pRL-SV40 control vector (Renilla
luciferase) was cotransfected as an internal control for transfection efficiency. After cells
treated with or without b-FGF (4ng/ml) and TNFα (10ng/ml) (R&D Systems) for 48h, cell
lysates were prepared and assayed for firefly and control Renilla luciferase using the Dual-
Luciferase reporter assay (Promega).
EMSA and supershift assays
Electrophoretic mobility shift assay (EMSA) and supershift assays were performed as
previously described (30). After Jurkat cells were stimulated with TNFα for 24h, nuclear
extract from Jurkat cells was prepared by NE-PER nuclear extraction reagent (Thermo
scientific). Biotin-labeled oligonucleotides were used to perform EMSA:
5'ACCCATTAAAAAC/GAATGGAAGACACTAT3' (forward) and
5'ATAGTGTCTTCCATTG/CTTTTTAATGGGT3' (reverse). EMSAs were performed with
the LightShift Chemiluminescent EMSA Kit (Pierce). The antibody used in the supershift
reactions was 2μl of polyclonal rabbit anti human SOX5 (Anti-SOX5) (Santa Cruz
biotechnology).
Statistical analysis
Comparisons between patient groups were made by 1-way analysis of variance (ANOVA)
for three groups (3 genotypes), and unpaired t-tests for two groups (dominant or recessive
models) for age of RA symptom onset. For comparison of mean values, Student's t-test was
performed. The strength of pair-wise linkage disequilibrium (LD) (r2) between two genetic
polymorphisms was assessed using Haploview 4.0. Statistical analyses were performed
using software package Prism 4 (GraphPad Software). P values < 0.05 were considered to
indicate statistical significance.
RESULTS
Fine-mapping RANKL SNPs for association with younger age of RA onset in EA patients
(Extended RF+ early RA WCPR cohort)
We previously observed a strong association between the combined presence of HLA-
DRB1*04 and RANKL polymorphisms (rs9525641 in the promoter region and rs922996 in
intron 4) with a younger age of RA onset in 182 RF+ EA early RA WCPR patients (21).
Because these two RA-associated SNPs showed no potential biologic functions based on
bioinformatic searches, we reasoned the observed association signals are likely to reflect
potential functional variants within the RANKL locus. To test this hypothesis, we assessed
16 SNPs located in the 48 kb RANKL genomic region using the enlarged discovery panel of
the 210 EA RF+ early RA WCPR patients.
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The minor allele of 4 RANKL SNPs, mainly in promoter (rs5803141, rs7984870 and
rs9525641 in promoter, and rs1054016 in 3'UTR) were associated with earlier age at RA
onset in EA patients (p < 0.05) (Figure 1A and B). These 4 SNPs are in strong linkage
disequilibrium (LD) (r2 = 0.75 ~ 0.94) with each other but showed modest LD (r2 = 0.57~
0.65) with the formerly observed RA-associated RANKL rs922996, the association of which
was not confirmed in this study.
The similarities in manifestations and genetic background between RF+ adult RA and RF+
polyarticular JIA (31) prompted us to test the potential association of these 4 SNPs with
juvenile arthritis in 80 EA RF+ polyarticular JIA patients. No significant association
between the minor allele of these SNPs and age of disease onset was observed in this cohort,
which might be attributed to the modest sample size and narrow range in age of disease
onset (median = 11.1 yrs; 25% to 75% percentile = 8.8 to 12.8 yrs).
Confirmation of the association of RANKL SNPs with younger age of RA onset in an
additional EA cohort (BRASS cohort) and AA cohort (CLEAR cohort)
To seek replication of the significant association of RANKL genotypes with age of RA onset,
we genotyped these four SNPs in two independent RA cohorts. One replication cohort was
501 independent EA early RA patients from BRASS. The strong LD of these 4 SNPs (r2 =
0.76 − 0.93) observed in BRASS cohort was similar to the LD values in WCPR EA cohort,
indicating BRASS is a well-matched independent cohort for replication study. Only the
rs7984870 CC allele was associated with earlier RA onset in 344 ACPA+ EA patients (37.6
± 12.8 yrs) compared to non-CC carriers (41.4 ± 14.6 yrs; p = 0.04) and a similar trend of
association in RF+ patients (CC vs. non-CC carriers, 37.9 ± 13.0 yrs vs. 41.4 ± 14.5 yrs; p =
0.08) (Figure 1A, Table 2).
The second independent replication panel included 298 AA RA patients from CLEAR
cohort. Genotypic association with younger age of RA onset was observed in two promoter
SNPs (rs5803141 and rs7984870) in an ACPA+ subset (n = 172) and a trend of this
association in RF+ AA RA patients (n = 211) (Figure 1A, Table 2), implicating a role of
RANKL promoter SNPs in development of RA in multiple ethnic groups.
Confirmation that the interaction between HLA-DRB1 SE and RANKL promoter contributes
to earlier age of RA onset in WCPR, BRASS and CLEAR RA cohorts
We previously reported a significant association of the co-occurrence of RANKL
polymorphisms and HLA-DRB1*04 with younger age at onset of RA in the original WCPR
cohort (21). In the present study, we defined the SE as containing any one of the following
HLA-DRB1 alleles: *0101, *0102, *0401, *0404, *0405, *0408, *0410, *1001, *1402,
*1406. The mean age at disease onset in RA patients harboring SE was an average of 4.7
and 4.5 years younger than that in patients without SE in seropositive (RF+ and/or ACPA+)
EA WCPR and BRASS RA cohort (p = 0.03 and 0.01, respectively), but this difference was
not observed in AA CLEAR RA cohort (Figure 2A). Among RF+ RA patients, co-
occurrence of SE and the CC allele of rs7984870 was associated with younger age at disease
onset with an average of 8.2 yrs (WCPR cohort), 4.7 yrs (BRASS cohort) and 6.7 yrs
(CLEAR cohort) younger than non-CC SE positive carriers (p = 0.004, 0.01 and 0.01,
respectively) (Figure 2 B–D). A similar trend of younger age at onset also was seen in
ACPA+ patients in BRASS and CLEAR cohorts (mean 5.1 and 5.7 yrs earlier; p =0.01 and
0.02) (Figure 2 C–D), suggesting co-occurrence of SE and RANKL risk alleles had a
stronger impact on the earlier age at disease onset than each gene variant individually.
However, these genetic associations were not observed in seronegative RA patients.
Stratifying RA patients into 0, 1 and 2 copies of SE subgroups, only ACPA+ BRASS EA
RA showed a trend toward a younger RA onset (supplementary Table 1). Of note, RANKL
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CC allele was not associated with early age at RA onset in 0 copy SE RA patients, which
might be attributed to the small sample size (n= 8~26 patients in each CC plus SE 0 copy
subgroup) and/ or in part because the effect of rs7984870 CC on age of RA onset might
depend on HLA-DRB1 (supplementary Table 1).
The HLA– DRB1*04 alleles represent a considerably stronger susceptibility factor than
other SE alleles in RA (32). When SE was defined as only HLA-DRB1*04 alleles (included
*0401, *0404, *0405, *0408, and *0410), the combined presence of SE-containing
DRB1*04 and rs7984870 CC genotype displayed an even earlier age of RA onset in RF+ or
ACPA+ patients (mean 13.3 yrs earlier in WCPR cohort, P =0.0003, mean 5.8 and 6.3 yrs
earlier in BRASS, P = 0.01 and 0.007, and mean 9 and 9.4 yrs earlier in CLEAR, P =0.01,
respectively) (Figure 2 B–D). Multiple regression analysis testing the interaction on age at
RA onset with the presence of SE and risk allele in rs7984870, confirmed a significant
interaction only in WCPR and BRASS EA RA patients (p < 0.05, respectively), indicating
that the interaction only existed in EA patients.
Our data indicated among the 4 SNPs identified in the initial discovery WCPR cohort, only
rs7984870 showed genetic association with younger age onset in 2 independent early RA
replication cohorts of EA and AA ancestries. The consistent association of rs7984870 with
RA led us to investigate its potential functional effect.
RANKL promoter SNP rs7984870 might affect RANKL expression level
Plasma levels of soluble RANKL (derived from membrane forms and measured by ELISA)
were compared to genotypes. Frozen plasma samples had been collected from the baseline
evaluation of WCPR RF+ EA RA patients who were still within 1 year of symptom onset
and had not yet been treated with DMARDs. Similar to a previous report (33), our study
found that soluble RANKL levels in plasma were significantly higher in RA patients (0.64 ±
0.61 pmol/L) compared to healthy controls (HC) (0.26 ± 0.18 pmol/L; p = 0.004). No
significant allelic-specific difference in RANKL levels was observed in HC. However,
soluble RANKL levels were approximately 2 - fold higher in RA patients carrying
rs7984870 CC genotype (0.87 ± 0.53 pmol/L) than in those carrying GG genotype (0.46 ±
0.67 pmol/L; p = 0.002; Figure 3A).
We subsequently tested whether rs7984870 variant would impact on RANKL transcription.
The relative expression of RANKL isoform 1 transcript (encodes RANKL1 and RANKL2 by
alternative splicing) and total RANKL transcript (isoform 1 plus isoform 2 that encodes
RANKL3) in PBMC were specifically measured using real-time PCR, and normalized using
the expression level of CD4 because RANKL is mainly expressed in activated T helper cells
in peripheral blood. Compared to isoform 1, isoform 2 has an upstream transcription start
site, suggesting it may be regulated differently. Transcript levels of RANKL isoform 2 were
generated from transcripts levels of total expression minus isoform 1 in this study. We did
not observe any allele-specific difference in mRNA expression of the two isoforms in
PBMC from HC (Figure 3B). RANKL mRNA expression in 22 RA patients (11 CC and 11
GG genotype for rs7984870) was also examined, but the allelic difference was not
conclusive, perhaps owing to a small sample size and/or disease activity (data not shown).
As shown in Figure 3B, higher expression of isoform 1 than isoform 2 was observed in
PBMC, similar to a previous report (15), consistent with isoform 1 being the major RANKL
transcript in blood circulation. We next tested the allelic expression levels of the major
RANKL isoform in T cells in vitro. The primary T cells from 8 normal controls (4 CC and 4
GG genotype for rs7984870) were treated with or without IL-2 20ng/ml for 24 or 48 h and
harvested to perform real-time PCR assays. RANKL expression was normalized using the
expression level of RPLPO. RANKL transcript levels were significantly increased after in
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vitro activation of T cells by co-culturing with IL-2 for 48h. Interestingly, T cells carrying
the rs798470 CC genotype conferred significantly higher RANKL transcript levels than those
carrying GG genotype after activation by IL-2 (p = 0.04, Figure 3C).
RANKL promoter SNP rs7984870 may affect the promoter activity
2-kb RANKL promoter luciferase constructs expressing either the major G allele or the
minor C allele at position −1816 were transiently transfected into the human stromal cell
line SAKA-T and osteoblast cell line hFOB1.19. Basic fibroblast growth factor (b-FGF) and
TNFα have been reported to upregulate RANKL expression (29;34). Transfection of the
rs7984870 CC RANKL promoter displayed a 40% increaseing transcription activity in
stromal cell lines and a 30% increase in osteoblast cell lines compared with GG genotype
after stimulation with b-FGF; similarly, the promoter activity was increased significantly
more after stimulation with TNFα when these two cell lines were transfected with
rs7984870 CC construct compared with GG construct (p < 0.05, Figure 4 A–B).
rs7984870 CC genotype may create a binding site to transcription factor SOX5
To investigate the effect of the polymorphism on transcription factor binding, EMSA assay
was performed. The 28-bp oligonucleotide containing the homozygous minor C allele or the
major G allele of rs7984870 was incubated with nuclear extracts prepared from Jurkat cells
after stimulation with TNFα for 24h. Binding of nuclear proteins was observed with the
oligonucleotide probe containing either the GG or the CC allele (Figure 4C, lane 2 and 5). In
silico analysis indicated that transcription factor SOX5 might bind to the rs7984870 CC
allele but not to the GG allele. The addition of commercial polyclonal rabbit IgG antibodies
to SOX5 produced a supershift band only in CC allele (Figure 4C lane 8) but not in GG
allele (Figure 4C, lane 10), suggesting only rs7984870 CC allele could bind to the SOX5
transcription factor. The addition of rabbit IgG failed to produce a supershift band (Figure
4C, lanes 7 and 9). Binding to each oligonucleotide probe was competed by a 200-fold
excess of unlabeled specific oligonucleotide (Figure 4C, lanes 3 and 6).
DISCUSSION
Although the role of RANKL in RA has been well established, little is known about the
contribution of its genetic variations to RA onset. We previously observed a strong
association between the combined presence of HLA-DRB1*04 and RANKL polymorphisms
with a younger age of RA onset in 182 RF+ EA early RA WCPR patients (21). In this
extended study of 210 RF+ RA WCPR patients, we fine mapped the RANKL locus and
observed association of the minor allele of 4 SNPs (rs5803141, rs7984870, rs9525641 and
rs1054016) with younger age at RA onset. Subsequent replication studies of these 4 SNPs
showed association of a single SNP in the promoter, the minor C allele of rs7984870, with
younger age of RA onset in two independent cohorts (ACPA+ EA BRASS and AA
CLEAR). These two independent RA cohorts were early RA (<24 months after symptom
onset) long-term observational cohorts, and have an accurately documented date of RA
onset similar to WCPR cohort.
In both the previous (21) and extended WCPR cohort, the association between rs9525641
and younger age of RA onset was present; however, the formerly observed RA-associated
rs922996 was not confirmed. Recently, a RANKL intron 1 rs2277438 has been associated
with RA in European population (534 cases and 516 controls) (35). This SNP was also
tested in our WCPR EA cohort, but had weak LD with promoter SNP rs7984870 (r2 = 0.17)
and did not show the association with age of disease onset. Possible explanations for the
inability to replicate RANKL SNPs (rs5803141, rs9525641, rs922996, rs1054016 and
rs2277438) in some of the studied cohorts include genetic, ethnic, and clinical heterogeneity
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across study populations as well as the probability that these SNPs may be linked to the
actual RANKL causal allele. Several genome-wide association studies (GWAS) in RA have
identified and replicated more than 20 risk loci (2;5), but have not included the RA-
associated RANKL SNP described here. Given that the association with younger age of RA
onset was only observed in CC homozygotes, we used a recessive genetic model to estimate
the power of GWAS to capture this risk allele under the assumption of relative risk of 1.3
(36). A sample size of 10,000 cases and 10,000 controls could provide 65% power to reach a
p value of 10−7, which might explain why this SNP was not identified in previous GWAS in
RA (2;5;36;37). However, the consistent presence of the observed genetic association in 3
independent panels and the functional properties of the rs7984870 allele in transcription
regulation of RANKL in our study make this promoter polymorphism an excellent candidate
for a causal variant contributing to younger age of RA onset.
SE is a recognized genetic risk predisposing to RA onset and serves as a binding site for
arthritogenic peptides, allowing their presentation to CD4+ T cells. Similar to our previous
report, the co-occurrence of rs7984870 risk allele and SE displayed the earliest age of RA
onset in RF+ or ACPA+ RA patients. One possible hypothesis is that co-occurrence of
RANKL polymorphisms and SE contributed to younger RA onset in ACPA+/RF+ patients
by causing abnormally stimulated RANKL expression, which dysregulates dendritic/T cell
communication and breaks the immune tolerance to self-components in the joint, thereby
enhancing T-cell reactivity towards arthritogenic antigens.
A growing number of genetic variants have been reported to contribute to ACPA+ RA (6–
11). In our replication studies performed in 298 AA and 501 additional EA patients, the
significant genetic association of rs7984870 with earlier RA onset was only shown in the
ACPA+ patients but not in ACPA− RA, suggesting that the RANKL allele might be a novel
disease predisposing variant in ACPA+ RA subset. Alternatively, the lack of a significant
association might be attributed to the modest sample size of seronegative RA patients used
in these studies.
Our study provides evidence that risk C allele of rs7984870 conferred a 2-fold higher
plasma soluble RANKL level in RF+ RA patients and significantly elevated RANKL isoform
1 mRNAs expression by activated control T cells, as well as increased promoter activity
after cytokine stimulation in vitro. Over expression of RANKL results in functional alteration
of epidermal DCs (38) and enhances survival of DCs (13). Transfer of RANKL-stimulated
MRL/lpr DCs pulsed with collagen into MRL/lpr mice have been shown acceleration
autoreactivity of T and B cells and enhance the productions of pathogenic cytokines in the
recipients (13). The minor C allele of rs7984870 contributed to higher RANKL expression
and protein level upon activation and thus, might affect initiation of immune responses
between DCs and T cells. In addition, immunoreceptor tyrosine-based activation motif
(ITAM) associated receptor networks have been implicated in providing co-stimulation for
RANKL signaling (39); thus, another possible explanation is that genetic variants causing
differences in RANKL expression could therefore result in abnormal cross-talk in signaling
networks and alteration of cellular responses to various extracellular stimuli.
An important issue is how this RANKL variant affects the expression of RANKL. Our data
suggests that the minor C allele of rs7984870 creates a binding site for transcription factor
SOX5, a member of the SOX family, which might explain observed alterations in RANKL
transcription. SOX family have been primarily characterized as important transcriptional
regulators involved in determination of cell fate and tissue specification during a number of
developmental processes (40). Elevated SOX5 transcripts have been related to invasive
growth and reduced apoptosis in tumors and have been associated with progression of
certain cancers (41–43). Recently, SOX6, another member of the SOX family, which shares
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91% amino acid homology in the leucine-zipper motif with SOX5, was identified as a low
bone mineral density locus in a large-scale meta-analysis of GWAS studies (44). Taken
together, the differential binding of the minor C allele of rs7984870 to SOX5 transcriptional
regulator might influence bone metabolism, and facilitate invasive growth and resistance to
apoptosis in the synovium, leading to RA manifestations.
In summary, the association of CC genotype of rs7984870 with younger RA onset was
identified and replicated in several independent cohorts in this study. This novel genetic risk
factor, RANKL rs7984870 CC genotype, conferred elevated promoter activity after
stimulation by cytokines, potentially via binding to transcription factor SOX5. Elevated
inducible RANKL mRNA and protein levels might result in enhanced interaction between
activated T cells presenting arthritogenic peptides to DCs, predisposing to earlier
development of seropositive (RF+ or ACPA+) RA in EA and AA patients. Our evidence
suggests that the combination of CC genotype of rs7984870 RANKL polymorphism, SE, and
abnormal humoral immune responses interacts to permit an earlier onset of RA.
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RANKL structure with tested SNPs and haplotype blocks in EA and AA patients. A. The
−log10 base of genotypic p value for each SNP (comparing those homozygous for the minor
allele vs. those homozygous for the major allele plus heterozygote) is shown as diamond
(210 RF + WCPR EA), triangle (344 ACPA + BRASS EA) and circle (172 ACPA +
CLEAR AA). The 2 SNPs (rs9525641 and rs922996) showed with box is reported in our
previous study. Four RANKL SNPs (rs5803141, rs7984870, rs9525641 and rs1054016) in
WCPR EA RA patients showed significant association with early age RA onset, and these 4
SNPS were selected for replication studies. B. The relative position of 5 exons of RANKL is
depicted. The start (ATG) and the end (TGA) of the ORF (Open Reading Frame) are
indicated on RANKL1, 2 and RANKL3. C. Schematic structure of RANKL promoter
luciferase (Luc) reporter gene construct.
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Association of shared epitope (SE) and RANKL rs7984870 CC allele with age of RA onset.
A. Association of SE with age of RA onset in seropositive WCPR, BRASS and CLEAR
early RA cohort. B–D. Co-occurrence rs7984870 CC allele and SE negative, SE positive, as
well as DRB1*04 positive with age at RA onset in seropositive and seronegative WCPR (B),
BRASS (C) and CLEAR (D) early RA cohort. SE was defined as presence of any one the
following HLA-DRB1 alleles: *0101, *0102, *0401, *0404, *0405, *0408, *0410, *1001,
*1402 and *1406. HLA–DRB1*04 alleles included *0401,*0404, *0405, *0408, and *0410.
Mean age of RA onset in each group is shown on the top of column.
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Association of RANKL genotypes with expression levels of mRNA and secreted protein. A.
Soluble RANKL levels from serum samples of healthy controls (HC) who were homozygote
for either the minor C allele or the major G allele of RANKL promoter SNP rs7984870 (CC
= 5 vs. GG = 19), and those from WCPR RA patients at study entry before DMARD
treatments (CC = 10 vs. GG = 13). Data are means of triplicate experiments ± SD. B.
Relative mRNA expression levels of two RANKL isoforms in PBMCs from HC who were
homozygous for the minor C allele or the major G allele of rs7984870 (CC = 17 vs. GG =
21). C. Relative mRNA expression levels of RANKL isoform 1 in isolated T cells from HC,
who were homozygous for the minor C allele or the major G allele of rs7984870 (CC = 4 vs.
GG = 4), were determined at various time points during co-culture with or without IL-2. The
mRNA expression results represent the mean ± SD of two independent experiments
performed in triplicate.
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Allelic differences in transcriptional and DNA-binding properties of rs7984870 variants. A–
B. SAKA-T (left) and hFOB 1.19 (right) cell lines were transfected with a luciferase (Luc)
reporter gene driven by RANKL promoter sequences (−2000/−1) containing either the CC or
GG allele of rs7984870 and cultured in the presence and absence of b-FGF (4 ng/ml) (A) or
TNFα (10 ng/ml) (B). Luciferase activity is displayed as the mean ± SD of three
independent experiments performed in triplicate. C. Shift, and supershift and competition
experiments with Jurkat nuclear cell extract and allelic variants of rs7984870. The 28-bp
oligonucleotide containing the rs7984870 CC or GG allele were incubated with nuclear
extracts prepared after stimulation with TNFα for 24h. The band that was either a shift
(below) or supershift (above) was indicated by an arrow. D. Proposed model of interaction
between the allelic variants of rs7984870 with the transcription factor SOX5.
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Table 1
Clinical characteristics of the RA and JIA patients
RA JIA
Clinical characteristics EA WCPR (n=210) EA BRASS (n=501) AA CLEAR (n=298) EA RF+ Polyarticular JIA(n=80)
Female (n, %) 157 (74.8%) 403 (80.4%) 246 (82.6%) 69 (86.3%)
Age at disease onset (yrs)* 51.4 ± 13.1 41.8 ± 15.2 49.8 ± 13.3 10.4 ± 4.0
Baseline disease duration* (months) 6.1 ± 3.3 9.9 ± 6.2 13.2 ± 7.4 -
RF+ (n, %) 210 (100%) 317 (63.3%) 211 (70.8%) 80 (100%)




Patients recruited from 1993, no ACPA record.
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